miRNAs antagonistic to BDNF expression, such as miR-101 and miR-107, have been studied for the targeted treatment of prostate cancer, and the previously mentioned drugs, such as Cabozantinib, Larotrctinib, and Entrctinib, have been developed. This evidence concerns the gene BDNF and prostate carcinoma.